Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tiziana Life Sciences Ltd

Tiziana Life Sciences PLC surged 19% to 73p after signing an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL). The pair will explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies.

Tiziana Life Sciences surges on exclusive licensing agreement with Precision BioSciences

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana's foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies. CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene (now owned by Bristol Myers Squibb) and Gilead Sciences (NASDAQ:GILD) underscore the interest in this emerging area of biotechnology.

Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy

DURHAM, N.C., NEW YORK & LONDON--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a clinical stage biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an exclusive license agreement to explore Tiziana's foralu

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Precision uses its ARCUS genome editing method to overcome cancers and cure genetic diseases. This is different from CRISPR, another gene editing technology which has recently been the subject of an adverse study report, highlighting the safety profile.

Precision BioSciences: The Right Profile To Progress

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will host its first R&D event focused on in vivo gene editing at 8:00 am ET on Thursday, September 9, 2021. Precision's gene editing event will feature presentations from Company management as well as featured guest speakers and will outline Precisio

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 194.74% and 202.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Surpasses Q2 Earnings and Revenue Estimates

Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year over year to $0.36, which beat the estimate of ($0.44).

Precision BioSciences: Q2 Earnings Insights

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “In the second quarter of 2021, we continued to execute on our ARCUS-edited allogeneic CAR T programs, including our anti-CD19 studies. We continue to monitor for durabi

Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with i

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate.

Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that the first patient has been dosed in its Phase 1 clinical trial with PBCAR19B, an immune evading allogeneic CAR T stealth cell candidate for patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). “We are excited to have dosed the first patient i

Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?

The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 6%. This is why it happened.

DTIL Stock Price Increased Over 6%: Why It Happened

SpringWorks Therapeutics Inc

Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.  In the study, Precision's investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks' investigational gamma-secretase inhibitor in relapsed/refractory multiple myeloma.

Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial

DURHAM, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combinat

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced encouraging progress on two strategies designed to optimize the durability of allogeneic CAR T therapy in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The Company reported updated interim results from its Phase 1/2a study of PBCAR0191, the

Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo. The study, “Mitochondrial targeted meganuclease as a platform to elimina

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company's Interim Chief Financial Officer since December 2020. He will continue to serve as the c

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021. Details for the fireside chat are below: Jefferies Virtual Healthcare Conference D

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting CD19. Data will be presented at the 2021 American Society of Clinical Oncology Meeting.

Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that additional data from its Phase 1/2a study of PBCAR0191, the Company's first generation, off-the-shelf allogeneic CAR T candidate targeting CD19 will be presented at the 2021 American Society of Clinical Oncology (ASCO) Meeting being held virtually June 4-8, 2021. Abstracts are available and can b

Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting

Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were up 36.54% year over year to ($0.33), which beat the estimate of ($0.50).

Recap: Precision BioSciences Q1 Earnings

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “In the first quarter, we have worked diligently to advance our ARCUS-based in vivo gene editing and allogeneic CAR T pipelines,” commented Matt Kane, CEO and co-founder

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

The stock price of Precision BioSciences Inc (NASDAQ: DTIL) increased by over 10% during intraday trading. This is why it happened.

News for Precision Biosciences Stock (DTIL)